Company / Return on Assets (ROA)
RIGEL PHARMACEUTICALS INC Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
71.5%
FY2025
5-year range
-43.6% / 71.5%
FY2021-FY2025
Trend
+570.4%
vs FY2024
Sector context
#1 of 213
Health Care
What the data says
Return on Assets (ROA) changed +570% YoY in FY2025, a notable deviation from the 9-year average annual change of +69%.
Based on SEC 10-K filings.
71.5% in FY2025 with a 5-year CAGR of +98.4%. Ranks 1st among 213 companies in Health Care.
Improved from -21.4% to 71.5% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +115.1pp
- 5-Year Change
- +98.4pp
- 10-Year Change
- -
Sector benchmark
Top 0% in Health CareTop 0% of 213This company 71.5% Sector average -24.2%
▼
+395.7% above sector average
Key checks
Key Insights
- RIGEL PHARMACEUTICALS INC's return on assets (roa) has grown for 3 consecutive years.
- In FY2025, return on assets (roa) increased 570.4% year-over-year.
- Currently 95.6pp above the Health Care sector average.
- Lowest return on assets (roa) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 71.5% | +570.4% |
| FY2024 | 10.7% | +149.8% |
| FY2023 | -21.4% | +50.9% |
| FY2022 | -43.6% | -307.3% |
| FY2021 | -10.7% | +60.3% |
| FY2020 | -27.0% | +40.5% |
| FY2019 | -45.3% | +8.9% |
| FY2018 | -49.8% | +24.0% |
| FY2017 | -65.5% | +26.1% |
| FY2016 | -88.6% | -126.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026